[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342163-105":59,"doc-detail-342163-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","polyethylene-glycol-phospholipid-functionalized-single-walled-carbon-nanotubes-for-enhanced-sirna-systemic-delivery","Polyethylene glycol-phospholipid functionalized single-walled carbon nanotubes for enhanced siRNA systemic delivery","","Small interfering RNAs (siRNA) are a promising therapeutic tool for gene silencing, yet clinical delivery has largely remained localized, limiting systemic use. This work develops a systemic delivery vehicle (SWNTsiRNA) using single-walled carbon nanotubes functionalized with PEGylated phospholipids containing amine (PA) or maleimide (MA). Lower molecular weight PA yields the most stable conjugates with high siRNA loading. In vitro delivery shows energy-dependent uptake in tumour and HEK293T cells with low toxicity, and P-glycoprotein does not block delivery. A mouse xenograft model confirms significant gene knock-down with no acute toxicity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/polyethylene-glycol-phospholipid-functionalized-single-walled-carbon-nanotubes-for-enhanced-sirna-systemic-delivery/342163/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/polyethylene-glycol-phospholipid-functionalized-single-walled-carbon-nanotubes-for-enhanced-sirna-systemic-delivery/342163.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is systemic siRNA delivery difficult compared with localized delivery?","Question",{"text":112,"@type":113},"Systemic delivery is limited by instability of siRNA in bloodstream, inefficient membrane penetration and endosomal escape, and rapid kidney clearance. These factors reduce therapeutic interaction time with target cells and weaken gene-silencing efficacy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the SWNTsiRNA vehicle constructed in this study?",{"text":117,"@type":113},"Single-walled carbon nanotubes were functionalized with PEGylated phospholipids and conjugated to siRNA. The study compared phospholipid derivatives containing amine (PA) versus maleimide (MA) to optimize stability and loading.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports the delivery performance and safety of the SWNTsiRNA conjugates?",{"text":121,"@type":113},"In vitro experiments show high stability, high siRNA loading, energy-dependent cellular uptake in multiple tumour cell lines and HEK293T cells, and low toxicity. In vivo xenograft experiments confirm significant gene knock-down without signs of acute toxicity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342163,1790490972,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nPolyethylene glycol-phospholipid functionalized single-walled carbon nanotubes for enhanced siRNA systemic delivery  \nYuen-Fen Tan1,2,3, Ling-Wei Hii1, Wei-Meng Lim1,4, Soon-Keng Cheong5, Chee-Onn Leong1,6,7, Maxine Swee-Li Yee8􀀍 & Chun-Wai Mai1,9􀀍  \nSmall interfering RNAs (siRNA) technology has emerged as a promising therapeutic tool for human health conditions like cancer due to its ability to regulate gene silencing. Despite FDA-approved, their delivery remains localized and limiting their systemic use. This study used single-walled carbon nanotubes (SWNTs) functionalized with polyethylene glycolated (PEGylated) phospholipids (PL-PEG) derivatives for systemic siRNA delivery. We developed an siRNA systemic delivery vehicle (SWNTsiRNA) by conjugating SWNT functionalized with PL-PEG containing either amine (PA) or maleimide (MA). The functionalized SWNT with a lower molecular weight of PA produced the SWNT-siRNA conjugate system with the highest stability and high siRNA loading quantity. The system delivered siRNA to a panel of tumour cell lines of different organs (i.e. HeLa, H1299 and MCF-7) and a noncancerous human embryonic kidney 293 cells (HEK293T) with high biocompatibility and low toxicity. The cellular uptake of SWNT-siRNA conjugates by epithelial cells was found to be energy dependent. Importantly, the presence of P-glycoprotein, a marker for drug resistance, did not inhibit SWNTmediated siRNA delivery. Mouse xenograft model further confirmed the potential of SWNT-siRNA conjugates with a significant gene knock-down without signs of acute toxicity. These findings pave the way for potential gene therapy applications using SWNTs as delivery vehicles.  \nKeywords Single-walled carbon nanotubes, siRNA delivery, PEGylated phospholipid, Gene silencing  \nThe potential of small interfering RNAs (siRNA) technology as a promising therapeutic intervention for diseases like cancer is undeniable. The Food and Drug Administration (FDA) approved the first siRNA drug, patisiran in August 2018 1; givosiran in November 2019 2; and lumasiran in November 2020. At present, seven siRNA drugs, namely vutrisiran, nedosiran, inclisiran, fitusiran, teprasiran, cosdosiran, and tivanisiran, are being evaluated in Phase III clinical trials3–5. While these agents showed promising results, their application is primarily limited to localized delivery to a certain target organ. This limitation makes these agents less useful for systemic diseases such as cancers that can metastasise to other organs, systemic autoimmune disorders, systemic infections, or genetic diseases that affect multiple organ systems. As such, it is pivotal to break through this challenge to design an effective siRNA agent for the treatment of systemic diseases.  \nSystemic delivery for siRNA therapeutics remained a significant challenge due to a variety of biological and technical factors. One of the key obstacles is maintaining the stability of siRNA molecules in the bloodstream, as they are prone to quick degradation by serum nucleases6. Additionally, these molecules need to efficiently penetrate cell membranes and escape endosomes to enact their gene-silencing effects—a feat that is challenging to achieve6,7. The kidneys can swiftly remove siRNA molecules from circulation, reducing their time to interact with target cells, which hampers the therapeutic efficacy6,7. Further, siRNA may inadvertently interfere with  \n1Centre for Cancer and Stem Cell Research, Institute for Research, Development and Innovation (IRDI), IMU University, Kuala Lumpur 57000, Malaysia. 2School of Postgraduate Studies, IMU University, Kuala Lumpur 57000, Malaysia. 3Cytovision Sdn. Bhd, Kuala Lumpur 57000, Malaysia. 4School of Pharmacy, Monash University Malaysia, Shah Alam 47500, Selangor, Malaysia. 5Centre for Stem Cell Research, M. Kandiah Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Shah Alam 43000","cbCaiaViPFeazw51","https://ap.wps.com/l/cbCaiaViPFeazw51","pdf",2402452,14,"English","# Background and challenge of systemic siRNA delivery\n# Design of the SWNTsiRNA delivery system\n## Functionalization strategy (PL-PEG-PA and PL-PEG-MA)\n# In vitro evaluation and cellular uptake\n# Drug resistance and off-target/biological effects\n# In vivo xenograft confirmation and implications","[{\"question\":\"Why is systemic siRNA delivery difficult compared with localized delivery?\",\"answer\":\"Systemic delivery is limited by instability of siRNA in bloodstream, inefficient membrane penetration and endosomal escape, and rapid kidney clearance. These factors reduce therapeutic interaction time with target cells and weaken gene-silencing efficacy.\"},{\"question\":\"How was the SWNTsiRNA vehicle constructed in this study?\",\"answer\":\"Single-walled carbon nanotubes were functionalized with PEGylated phospholipids and conjugated to siRNA. The study compared phospholipid derivatives containing amine (PA) versus maleimide (MA) to optimize stability and loading.\"},{\"question\":\"What evidence supports the delivery performance and safety of the SWNTsiRNA conjugates?\",\"answer\":\"In vitro experiments show high stability, high siRNA loading, energy-dependent cellular uptake in multiple tumour cell lines and HEK293T cells, and low toxicity. In vivo xenograft experiments confirm significant gene knock-down without signs of acute toxicity.\"}]","Polyethylene glycol-phospholipid functionalized single-walled carbon nanotubes for enhanced siRNA systemic delivery | PDF",1790045624,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45033808a3ab6582a60af47aa977ee3e.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6bdff7cc9a402b993e1a2b673dec4d8f.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d17db4c7ea0cff13c284981f1e1db83e.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f59b0597acf12b2c6430fe32ada3163c.webp",980,1287]